A review of 2023 and an outlook for 2024 and beyond, covering transactions in North America, Europe, Asia, and Latin America

Asbestos claims can pose significant financial burdens to corporate entities and insurers alike, necessitating effective strategies to manage and alleviate these liabilities.

We’re set to see in 2023 the fewest non-life Part VII transfers sanctioned by the UK since the early 2000s. What does the future hold for the strategy?

While we don’t expect IFRS 17 to fundamentally change insurance mergers and acquisitions in the short term, European insurers will likely increasingly focus on results over time.

Could legacy long-term care (LTC) blocks of business be the next wave of mergers and acquisitions, following the path of fixed-deferred annuities (FDAs)?

In 2022, life and health insurance transaction activity was down sharply. Our research points to the likely causes and projects the landscape for future mergers and acquisitions.

Success in mergers and acquisitions (M&A) often requires the potential acquirer to identify opportunities....

Acquiring a new business presents challenges for chief risk officers (CROs) and other risk professionals, especially when combining self-insured or large deductible insurance programs.

We review the M&A worldwide for life and health insurers in 2021, and an outlook for 2022 and beyond.

A significant benefit of a cyber risk assessment during M&A due diligence is that it presents the broadest view of how to value the cyber risk of a target company, while at the same time taking into account that company's…

In this article, we illustrate the sorts of analyses which are possible by looking at a sample of 24 transactions in Europe over the last couple of years across a wide range of EU markets.

The Solvency II Appraisal Value (SII-AV) provides a workable methodology for use in M&A transactions, which is aligned with the way that investors generally view potential target companies.